Category: Pathophysiology

Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19

Carlos Garcia-Prieto, Eva Musulen, Veronica Davalos,  et. al.doi: https://doi.org/10.1101/2024.07.03.601404 00010010 Abstract Severe Coronavirus disease 2019 (COVID-19) induces heterogeneous and progressive diffuse alveolar damage (DAD) highly disrupting lung tissue architecture and homeostasis, hampering disease management and leading to fatal outcomes. Characterizing DAD pathophysiology across disease progression is of ultimate importance to better understand the molecular and cellular features driving different DAD patterns and […]

Pathological sequelae of long-haul COVID

Posted on | Posted on John Murphy | Leave a Comment on Pathological sequelae of long-haul COVID

Saurabh Mehandru & Miriam Merad, Nature Immunology volume 23, pages194–202 ( Abstract The world continues to contend with successive waves of coronavirus disease 2019 (COVID-19), fueled by the emergence of viral variants. At the same time, persistent, prolonged and often debilitating sequelae are increasingly recognized in convalescent individuals, named ‘post-COVID-19 syndrome’ or ‘long-haul COVID’. Clinical symptomatology includes fatigue, malaise, dyspnea, defects […]

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Posted on | Posted on John Murphy | Leave a Comment on Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Chansavath Phetsouphanh, Brendan Jacka, et. al., Nature Communications volume 15, Article number: 3315 (2024) Abstract This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24 months. LC participants show elevated nucleocapsid IgG levels at 3 months, […]